Who can use Revolade(Eltrombopag)?

PROMACTA is approved for treating thrombocytopenia in immune thrombocytopenia, chronic hepatitis C, and severe aplastic anemia.

Indications

PROMACTA is indicated for adult and pediatric patients aged 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to other therapies. It is also used for thrombocytopenia in chronic hepatitis C patients to enable interferon-based therapy, and for severe aplastic anemia in combination with immunosuppressive therapy. The drug is not recommended for myelodysplastic syndromes or with certain antiviral regimens without interferon.